Design of Heme Protein Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
基本信息
- 批准号:6537007
- 负责人:
- 金额:$ 25.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-08-01 至 2005-03-31
- 项目状态:已结题
- 来源:
- 关键词:Escherichia coli biomaterial development /preparation blood /plasma substitute capillary chemical stability chimeric proteins circular dichroism conformation cytotoxicity free radical scavengers gene expression heme hemoglobin hemoprotein human tissue hydrogen peroxide intermolecular interaction ionic bond microspectrophotometry mutant myoglobin nitric oxide oxygen transport protein engineering recombinant proteins
项目摘要
DESCRIPTION: (Investigator's abstract) The long range goals are to develop O2
delivery pharmaceuticals based on extracellular recombinant hemoglobins (rHb).
These next generation rHbs will be designed for optimal O2 transport, minimal
interference with vasoregulation, enhanced resistance to denaturation, and
increased expression levels in E. coli. Seven required properties are: (a)
moderate O2 affinity (P50 5-30 mm Hg); (b) discrimination against CO binding;
(c) large rate constants for oxygen binding and release; (d) significantly
reduced rates of NO scavenging; (e) resistance to autooxidation and reactions
with H2O2 (f) low rates of hemin dissociation; and (g) highly stable apoglobin
structures. The mechanisms underlying these properties are being determined
using sperm whale myoglobin as a simple prototype for the alpha and beta
subunits of human hemoglobin, and the results are being used to develop
strategies for solving specific problems in the clinical use and commercial
development of extracellular hemoglobins (i.e., the hypertensive side effect
and production costs). These mutagenesis studies will provide a database for
evaluating more general principles for heme protein engineering. We will also
address fundamental physiological questions about O2 transport and NO signaling
and examine basic mechanisms of NO scavenging and O2 binding which apply to
other key heme proteins, including flavohemoglobin NO dioxygenases.
The specific aims for the next five years are to: (1) design new rHb products
with low rates of NO scavenging and more efficient O2 transport properties to
eliminate the hypertensive side effect of extracellular hemoglobin; (2)
determine the relative importance of P50, oxygen dissociation rate constants,
and cooperativity on O2 transport in capillaries in order to define the minimum
requirements for efficacy; (3) examine systematically all physiologically
relevant reactions of NO with the iron atom in hemoglobin to avoid other
potential side effects; (4) improve the in vivo stability and in vitro
shelf-life of recombinant hemoglobins by enhancing their resistance to
autooxidation, reaction with H2O2, and heme loss; and (5) increase expression
yields and lower cost of production in E. coli by enhancing the stability of
apohemoglobin.
描述:(研究者摘要)长期目标是发展O2
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN S. OLSON其他文献
JOHN S. OLSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN S. OLSON', 18)}}的其他基金
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2223331 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
3366209 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
3366210 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:
Design of Heme Protein-Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
- 批准号:
7844991 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2392678 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2901154 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
3366211 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:
Design of Heme Protein-Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
- 批准号:
7489686 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2223333 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2685381 - 财政年份:1991
- 资助金额:
$ 25.78万 - 项目类别:














{{item.name}}会员




